To form an intensity-based drug-sensing fluorescent reporter (iDrugSnFR), a circularly permuted GFP molecule, flanked by two 4-residue linking sequences, is inserted into a PBP at a position (77–78, …
The bottom lobe of the PBP is superimposed in the two conformations. With respect to the bottom lobe, the ‘Venus flytrap’ conformational change tilts the top lobe of the PBP but does not change its …
The display ranges from –10 to 715 kJ/mol. The molecules are shown on the same distance scale. Right: bond-line skeletal structures for the deprotonated forms.
Dose–response relations on intermediate constructs using E. coli lysate were performed with respective drug partners to identify site-saturation mutagenesis (SSM) winners. (A–D) The progenitor …
(A–D) Relevant EC50 values for each iDrugSnFR are listed in Table 2. Dashed lines indicate dose–response relations that did not approach saturation for the concentration ranges tested; therefore, EC5…
(A) iDianiSnFR shows no fluorescent response to any of the selected endogenous molecules. (B) iCytSnFR, (C) iCyt_F_SnFR, and (D) iCyt_BrEt_SnFR show no response to any of the selected endogenous …
Top row: exemplar heat traces of iCytSnFR, iCyt_F_SnFR, iCyt_BrEt_SnFR, and iDianiSnFR paired with their drug partners obtained by isothermal calorimetry. The heats for iCytSnFR, iCyt_F_SnFR, and …
Fluorescence was activated by mixing with the agonists as noted. Stopped-flow data shows a departure from first-order kinetics for this set of intensity-based drug-sensing fluorescent reporter …
(A) The red, blue, and black traces are mean ΔF/F0 values for the ACh (200 µM), cytisine (15 µM), and varenicline (2 µM) responses as a function of time (n = 4–10 areas per ligand). The ΔF/F0 was …
(A–D) Each iDrugSnFR detects its drug partner at the plasma membrane (PM) and endoplasmic reticulum (ER) of HeLa cells at the concentrations sampled. BC, buffer control. SEM of data are indicated by …
BC, buffer control. SEM of data are indicated by semi-transparent shrouds around traces where trace width is exceeded. Cyt (cytisine) in cells expressing iCytSnFR_ER (A) or iCytSnFR_PM (B); 10FC …
BC, buffer control. SEM of data are indicated by semi-transparent shrouds around traces where trace width is exceeded. (A) iCytSnFR and (B) iCyt_F_SnFR detect nicotine at both the plasma membrane …
Endoplasmic reticulum (ER)-targeted constructs of iDianiSnFR, iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR are shown before (A1–D1) and during (A2–D2) exposure to each drug partner. ER-targeted …
Cultured primary mouse hippocampal neurons were transduced with endoplasmic reticulum (ER)- or plasma membrane (PM)-targeted constructs. BC, buffer control. SEM of data are indicated by …
Endoplasmic reticulum (ER)-targeted constructs of iDianiSnFR, iCytSnFR, iCyt_F_SnFR, and iCyt_BrEt_SnFR are shown before (A1–D1) and during (A2–D2) exposure to each drug partner. ER-targeted …
(A) Example of the biphasic rising phase of a 1 µM cytisine response in an individual area (black trace, mean of four cells). Cytisine was applied for 30 s. The fast and slow time constants of the …
(A) The [Cytisine]-kfon relation was approximately linear between 1 and 15 µM cytisine. Symbols (filled squares) are the mean kfon for the individual cytisine concentrations tested (n = 7–10 areas …
PBP at the left; cpGFP at the right;key side chains in the linkers are shown as spheres. The ligand, varenicline, is shown as sticks.
PBP at the left; cpGFP at the right; key side chains in the linkers are shown as spheres. The ligand, varenicline, is shown as sticks.
The dianicline concentrations are shown. The scale bar is shown. The video is 25-fold faster than real time.
The dianicline concentrations are shown. The scale bar is shown.The video is 25-fold faster than real time.
The cytisine concentrations are shown. The scale bar is shown. The video is 25-fold faster than real time.
The cytisine concentrations are shown. The scale bar is shown. The video is 25-fold faster than real time.
Measurements in E. coli lysates (L) or with purified protein (P). ND, not determined. Data for iAChSnFR from Borden et al., 2019; data for iNicSnFR3b from Shivange et al., 2019.
Informal name | Drug of interest | ΔFmax/F0 | EC50 (µM) | S-slope | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L | P | L | P | L | P | 11 | 43 | 44 | 68 | 324 | 360 | 391 | 395 | ||
iNicSnFR3b | Nicotine | ND | 10 | ND | 19 | ND | 0.5 | E | E | N | H | S | T | F | G |
iDianiSnFR | Dianicline | 7.4 ± 0.1 | 4.7 ± 0.2 | 6.7 ± 0.3 | 15 ± 1 | 1.1 | 0.3 | D | R | - | S | N | G | - | N |
iAChSnFR | ACh | ND | 12 | ND | 1.3 | ND | 9.2 | I | V | N | H | A | T | F | G |
iCytSnFR | Cytisine | 5.0 ± 0.2 | 7.3 ± 0.4 | 9.4 ± 0.8 | 11 ± 1 | 0.5 | 0.7 | - | Y | - | - | - | - | W | - |
iCyt_F_SnFR | 10-Fluorocytisine | 7.9 ± 0.1 | 2.3 ± 0.1 | 1.4 ± 0.04 | 1.6 ± 0.3 | 5.6 | 1.4 | - | N | G | - | - | - | W | - |
iCyt_BrEt_SnFR | 9-Bromo-10-ethylcytisine | 4.0 ± 0.03 | 3.6 ± 0.04 | 5.7 ± 0.1 | 4.2 ± 0.2 | 0.7 | 0.9 | - | Q | G | - | - | - | W | - |
ND, not determined. *, ** EC50 and ∆Fmax/F0 could not be determined from the data (Figure 3). Therefore, the upper limit to the S-slope is estimated from the data at the foot of the dose–response …
Drug name | iDianiSnFR | iCytSnFR | iCyt_F_SnFR | iCyt_BrEt_SnFR | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ΔFmax/F0 | EC50 (µM) | S-slope | ΔFmax/F0 | EC50 (µM) | S-slope | ΔFmax/F0 | EC50 (µM) | S-slope | ΔFmax/F0 | EC50 (µM) | S-slope | |
Choline | 2.0 ± 0.1 | 84 ± 20 | < 0.1 | 5.8 ± 0.2 | 240 ± 30 | < 0.1 | 2.6 ± 0.1 | 18 ± 1 | 0.1 | 2.6 ± 0.1 | 12 ± 1 | 0.2 |
Acetylcholine | 7.4 ± 1.0 | 660 ± 80 | < 0.1 | 2.9 ± 0.1 | 35 ± 3 | < 0.1 | 4.4 ± 0.3 | 222 ± 50 | < 0.1 | 2.5 ± 0.2 | 73 ± 6 | <0.1 |
Cytisine | - | - | <0.1* | 7.3 ± 0.4 | 11 ± 1 | 0.7 | 4.4 ± 0.1 | 2.6 ± 0.3 | 1.7 | 4.7 ± 0.1 | 3.5 ± 0.2 | 1.3 |
Dianicline | 4.7 ± 0.2 | 15 ± 1 | 0.3 | 6.5 ± 0.4 | 34 ± 4 | 0.2 | 2.3 ± 0.3 | 43 ± 6 | < 0.1 | 4–6 | >100 | <0.1** |
Nicotine | 2.2 ± 0.1 | 440 ± 100 | < 0.1 | 6.4 ± 0.2 | 14 ± 2 | 0.5 | 4.7 ± 0.1 | 3.8 ± 0.2 | 1.2 | 4.8 ± 0.1 | 5.5 ± 0.2 | 0.9 |
Varenicline | 2.4 ± 2.0 | 1200 ± 500 | < 0.1 | 6.5 ± 0.1 | 0.06 ± 0.01 | 110 | 7.1 ± 0.2 | 0.09 ± 0.02 | 79 | 5.3 ± 0.1 | 0.06 ± 0.01 | 88 |
10-Fluorocytisine | ND | ND | ND | ND | ND | ND | 2.3 ± 0.1 | 1.6 ± 0.3 | 1.4 | 3.0 ± 0.1 | 4.7 ± 0.3 | 0.6 |
9-Bromo-10-ethylcytisine | ND | ND | ND | ND | ND | ND | 3.1 ± 0.1 | 31 ± 2 | 0.1 | 3.6 ± < 0.1 | 4.2 ± 0.2 | 0.9 |
Data are the mean ± SEM, three runs.
Biosensor | KD (μM) | n | ΔH(kcal/mol) | -TΔS(kcal/mol) | ΔG(kcal/mol) |
---|---|---|---|---|---|
iCytSnFR | 13.7 ± 1.1 | 0.84 ± 0.05 | –2.1 ± 0.1 | –4.6 ± 0.2 | –6.6 ± 0.1 |
iCyt_F_SnFR | 1.8 ± 0.5 | 0.83 ± 0.02 | –5.5 ± 0.1 | –2.4 ± 0.2 | –7.9 ± 0.1 |
iCyt_BrEt_SnFR | 5.4 ± 0.8 | 0.69 ± 0.09 | –1.12 ± 0.03 | 6.1 ± 0.1 | –7.2 ± 0.1 |
iDianiSnFR | 7.6 ± 1.4 | 0.92 ± 0.02 | 3.2 ± 0.5 | 10.1 ± 0.4 | –7.0 ± 0.2 |
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Strain, strain background (Escherichia coli) | BL21(DE3) | Agilent Technologies, Santa Clara, CA | 200131 | Chemically competent |
Cell line (Homo sapiens) | HeLa | ATCC | CCL-2;RRID:CVCL_0030 | |
Cell line (H. sapiens) | HEK293T | ATCC | CRL-3216;RRID:CVCL_0063 | |
Biological sample (Mus musculus) | Primary hippocampal neurons | Caltech animal facilities | RRID:IMSR_JAX:000664 | Freshly isolated from Mus musculus |
Recombinant DNA reagent | iAChSnFR | Loren Looger | Addgene: 137955 | Obtainable through Addgene |
Recombinant DNA reagent | iDianiSnFR | This paper | Addgene: 177741 | Obtainable through Addgene |
Recombinant DNA reagent | iCytSnFR | This paper | Addgene: 177738 | Obtainable through Addgene |
Recombinant DNA reagent | iCyt_F_SnFR | This paper | Addgene: 177739 | Obtainable through Addgene |
Recombinant DNA reagent | iCyt_BrEt_SnFR | This paper | Addgene: 177740 | Obtainable through Addgene |
Recombinant DNA reagent | pCMV(MinDis)-iDianiSnFR_PM | This paper | Addgene: 177751 | Obtainable through Addgene |
Recombinant DNA reagent | pCMV(MinDis)-iDianiSnFR_ER | This paper | Addgene: 177750 | Obtainable through Addgene |
Recombinant DNA reagent | pCMV(MinDis)-iCytSnFR_PM | This paper | Addgene: 177743 | Obtainable through Addgene |
Recombinant DNA reagent | pCMV(MinDis)-iCytSnFR_ER | This paper | Addgene: 177742 | Obtainable through Addgene |
Recombinant DNA reagent | pCMV(MinDis)-iCyt_F_SnFR_PM | This paper | Addgene: 177745 | Obtainable through Addgene |
Recombinant DNA reagent | pCMV(MinDis)-iCyt_F_SnFR_ER | This paper | Addgene: 177744 | Obtainable through Addgene |
Recombinant DNA reagent | pCMV(MinDis)-iCyt_BrEt_SnFR_PM | This paper | Addgene: 177747 | Obtainable through Addgene |
Recombinant DNA reagent | pCMV(MinDis)-iCyt_BrEt_SnFR_ER | This paper | Addgene: 177746 | Obtainable through Addgene |
Recombinant DNA reagent | pAAV9-hSyn-iDianiSnFR_PM | This paper | Addgene: 177759 | Obtainable through Addgene |
Recombinant DNA reagent | pAAV9-hSyn-iDianiSnFR_ER | This paper | Addgene: 177758 | Obtainable through Addgene |
Recombinant DNA reagent | pAAV9-hSyn-iCytSnFR_PM | This paper | Addgene: 177753 | Obtainable through Addgene |
Recombinant DNA reagent | pAAV9-hSyn-iCytSnFR_ER | This paper | Addgene: 177752 | Obtainable through Addgene |
Recombinant DNA reagent | pAAV9-hSyn-iCyt_F_SnFR_PM | This paper | Addgene: 177755 | Obtainable through Addgene |
Recombinant DNA reagent | pAAV9-hSyn-iCyt_F_SnFR_ER | This paper | Addgene: 177754 | Obtainable through Addgene |
Recombinant DNA reagent | pAAV9-hSyn-iCyt_BrEt_SnFR_PM | This paper | Addgene: 177757 | Obtainable through Addgene |
Recombinant DNA reagent | pAAV9-hSyn-iCyt_BrEt_SnFR_ER | This paper | Addgene: 177756 | Obtainable through Addgene |
Commercial assay or kit | Phusion High-Fidelity PCR Kit | New England Biolabs | E0553L | |
Commercial assay or kit | Q5 Site-Directed Mutagenesis Kit | New England Biolabs | E0554S | |
Commercial assay or kit | QIAprep Spin Miniprep Kit | QIAGEN SCR_008539 | 27104 | |
Commercial assay or kit | EndoFree Plasmid Maxi Kit | QIAGEN SCR_008539 | 12362 | |
Commercial assay or kit | QIAquick PCR Purification Kit | QIAGEN SCR_008539 | 28104 | |
Commercial assay or kit | QIAquick Gel Extraction Kit | QIAGEN SCR_008539 | 28704 | |
Commercial assay or kit | AAVpro Purification Kit | Takara Bio Inc. | 6666 | |
Commercial assay or kit | PACT premier | Molecular Dimensions | MD1-29 | |
Chemical compound, drug | 10-Fluorocytisine | Tim Gallagher | Rego Campello et al., 2018 | |
Chemical compound, drug | 9-Bromo-10-ethylcytisine | Tim Gallagher | Rego Campello et al., 2018 | |
Chemical compound, drug | Lipofectamine 2000 Transfection Reagent | Thermo Fisher Scientific | 11668027 | |
Chemical compound, drug | Lipofectamine 3000 Transfection Reagent | Thermo Fisher Scientific | L3000015 | |
Software, algorithm | Spartan’20 | Wavefunction, Inc. | RRID:SCR_014901 | |
Software, algorithm | NanoAnalyze | TA Instruments | https://www.tainstruments.com/sw/nano_analyze.html | |
Software, algorithm | OriginPro 2018 | OriginLab | RRID:SCR_014212 | |
Software, algorithm | KaleidaGraph | Synergy | RRID:SCR_014980 | |
Software, algorithm | ImageJ | NIH | RRID:SCR_003070 | |
Software, algorithm | XDS Program Package | MPI for Medical Research, Heidelberg | RRID:SCR_015652 | |
Software, algorithm | Phenix | Phenix | RRID:SCR_014224, SCR_016736 | Adams et al., 2010 |
Software, algorithm | Coot | MRC Laboratory of Molecular Biology | RRID:SCR_014222 | Emsley et al., 2010 |
Data collection and refinement statistics of iNicSnFR 3a.
Stopped-flow model determined rate constants.